Literature DB >> 9697665

Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome.

K Nakanishi1, K Iijima, N Kuroda, Y Inoue, Y Sado, H Nakamura, N Yoshikawa.   

Abstract

X-Linked Alport syndrome is caused by mutations in the type IV collagen alpha5 chain gene. Male patients usually develop end-stage renal disease, whereas female patients have more variable phenotypes from asymptomatic hematuria to end-stage renal disease. The variable phenotypes in female patients may be attributable to different X-chromosome inactivation patterns. Therefore, the correlation between disease severity and the degree of alpha5 chain expression in the epidermal basement membrane of female patients with X-linked Alport syndrome was examined. To estimate the disease severity in X-linked Alport syndrome, the ratios of protein to creatinine in single voided urine samples were used. Expression of the alpha5 chain in the epidermal basement membrane was examined by an indirect immunofluorescence method using an anti-alpha5 chain monoclonal antibody. A total of 25 female patients with X-linked Alport syndrome from 17 families was examined. Multiple regression analysis using disease severity as the response variable, and age, family history of nephritis, female and male family history of end-stage renal disease, serum creatinine concentration, and alpha5(IV) expression ratio in the epidermal basement membrane as explanatory variables showed that only alpha5(IV) expression ratio was a significant factor, and that it showed a highly significant negative association with disease severity (adjusted r2=0.71, P=0.0001). These findings suggest that variable alpha5 chain expression, possibly caused by different X-inactivation patterns, is responsible for the variable disease severity in female patients with X-linked Alport syndrome, and that immunohistochemical examination of alpha5 chain expression in the epidermal basement membrane may be a simple and useful method for predicting patient outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697665     DOI: 10.1681/ASN.V981433

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  12 in total

1.  X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene.

Authors:  Xue Jun Fu; Kandai Nozu; Aya Eguchi; Yoshimi Nozu; Naoya Morisada; Akemi Shono; Mariko Taniguchi-Ikeda; Yuko Shima; Koichi Nakanishi; Igor Vorechovsky; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-11-18       Impact factor: 2.801

2.  Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome.

Authors:  Tomoko Horinouchi; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Takashi Omori; Keita Nakanishi; Junya Fujimura; Akira Ashida; Mineaki Kitamura; Mitsuhiro Kawano; Wataru Shimabukuro; Chizuko Kitabayashi; Aya Imafuku; Keiichi Tamagaki; Koichi Kamei; Kenjirou Okamoto; Shuichiro Fujinaga; Masafumi Oka; Toru Igarashi; Akinori Miyazono; Emi Sawanobori; Rika Fujimaru; Koichi Nakanishi; Yuko Shima; Masafumi Matsuo; Ming Juan Ye; Yoshimi Nozu; Naoya Morisada; Hiroshi Kaito; Kazumoto Iijima
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

3.  Severe Alport syndrome in a young woman caused by a t(X;1)(q22.3;p36.32) balanced translocation.

Authors:  Kazumoto Iijima; Kandai Nozu; Koichi Kamei; Makiko Nakayama; Shuichi Ito; Kentaro Matsuoka; Tsutomu Ogata; Hiroshi Kaito; Koichi Nakanishi; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2010-04-13       Impact factor: 3.714

4.  X-linked Alport syndrome caused by splicing mutations in COL4A5.

Authors:  Kandai Nozu; Igor Vorechovsky; Hiroshi Kaito; Xue Jun Fu; Koichi Nakanishi; Yuya Hashimura; Fusako Hashimoto; Koichi Kamei; Shuichi Ito; Yoshitsugu Kaku; Toshiyuki Imasawa; Katsumi Ushijima; Junya Shimizu; Yoshio Makita; Takao Konomoto; Norishige Yoshikawa; Kazumoto Iijima
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-02       Impact factor: 8.237

5.  Discordance between skin biopsy and kidney biopsy in an X-linked carrier of Alport syndrome.

Authors:  Lorraine A Hamiwka; David H George; Silviu Grisaru; Julian P Midgley
Journal:  Pediatr Nephrol       Date:  2007-02-10       Impact factor: 3.714

6.  X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome.

Authors:  Michelle N Rheault; Stefan M Kren; Linda A Hartich; Melanie Wall; William Thomas; Hector A Mesa; Philip Avner; George E Lees; Clifford E Kashtan; Yoav Segal
Journal:  Nephrol Dial Transplant       Date:  2009-10-23       Impact factor: 5.992

Review 7.  Population-based studies reveal an additive role of type IV collagen variants in hematuria and albuminuria.

Authors:  Moumita Barua; Andrew D Paterson
Journal:  Pediatr Nephrol       Date:  2021-02-26       Impact factor: 3.714

Review 8.  Women and Alport syndrome.

Authors:  Michelle N Rheault
Journal:  Pediatr Nephrol       Date:  2011-03-05       Impact factor: 3.714

9.  A Novel Mutation in a Japanese Family with X-linked Alport Syndrome.

Authors:  Yoshifusa Abe; Masayuki Iyoda; Kandai Nozu; Satoshi Hibino; Kei Hihara; Yutaka Yamaguchi; Tomohiko Yamamura; Shogo Minamikawa; Kazumoto Iijima; Takanori Shibata; Kazuo Itabashi
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

10.  The variable course of women with X-linked Alport Syndrome.

Authors:  Priya Raju; David Cimbaluk; Stephen M Korbet
Journal:  Clin Kidney J       Date:  2013-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.